AbCellera, a company, is based in Vancouver, British Columbia.
11 reports, 5 independent
Updated Sep 16
Gone quiet
- Reports
- 11
- Developments
- 5
- Repetition
- 55%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbCellera, a company, is based in Vancouver, British Columbia.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AbCellera presented data in Rio de Janeiro.1 source
AbCellera CEO featured in B.C. industry discussion.1 source
AbCellera is based in Vancouver, British Columbia.1 source
Murray McCutcheon partnered with AbCellera, a Vancouver-based company.1 source
- Murray McCutcheon partners with Vancouver-based AbCellera.
Keep exploring
Part of
A company headquartered in Vancouver, BC, reports to its Board of Directors.Also in this story
- Tower Resources PLC operates under British Columbia jurisdiction and is headquartered in Vancouver, BC.
- Destiny Media Technologies Inc., headquartered in Vancouver, announced its Q3 financial results.
- Wishpond Technologies Ltd. used Vancouver as the filing location for corporate announcements on May 27, 2026.
The entities involved
-
Vancouver
largest city in the province of British Columbia, Canada
-
AbCellera
company in Vancouver, Canada
Nothing else this week.
Related events
- A company is headquartered in Vancouver, Canada.
- Announcements originated from the city of Vancouver on September 25, 2026.
- A company operates from the British Columbia region.
- A company has been listed on the Vancouver stock exchange.
- HydroGraph Clean Power Inc. announced on August 1, 2026, that its headquarters are located in British Columbia, announced from Vancouver, British Columbia.
Coverage
Newest first; wire copies grouped- standard-freeholder.com
- montrealgazette.com
- montrealgazette.com
- thestarphoenix.com
- theglobeandmail.com
- Business WireAbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of a
- Business WireAbCellera to Participate at Upcoming Investor Conferences in September VANCOUVER, British Columbia, August 12, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will pa
- Business WireAbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms VANCOUVER, British Columbia, August 07, 2025--(BUSINESS WIRE)--AbCe
- Unknown outlet